InvestorsHub Logo
Followers 119
Posts 7889
Boards Moderated 0
Alias Born 09/02/2011

Re: Don post# 15082

Tuesday, 03/14/2017 1:09:23 PM

Tuesday, March 14, 2017 1:09:23 PM

Post# of 73619
Good point! Do you think once 1000's of DOCS at the DFCon conference March 23-25, will be excited to hear about these results?? Let alone entry into the MMJ space?

"The results conclude Viabecline is more effective than standard care in treating DFU's, including IV antibiotics. The effect was greatest in those with the most severe wounds, i.e., large wounds that affect deeper anatomical structures. These patients were last resort patients that had failed all previous care and were headed to an amputation. In some cases, even an amputation wasn't feasible because of the patient's cardiac status. Viabecline is more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said CEO Dr. Christopher Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."

"announced today several patients have had significant treatment success with the use of its innovative transdermal system for the delivery of its FDA registered drug, Viabecline. Significant results have been achieved in just 10 days of treatment using ViaDerma's proprietary transdermal delivery system. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas. The "Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. For example, a deep wound with the hip bone exposed, had significant healing results, at the Dar Al Zahraa Hospital in Tripoli, Lebanon, after just 10 days. ViaDerma is seeing amazing penetration and absorption with localized wound treatment. "We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido," said CEO Dr. Christopher Otiko.
Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
Market for the following Drugs:
Topical antibiotics - $6 billion/year
Toenail antifungal drugs - $3 billion/year
Diabetic amputations - $3 billion/year
Global acne - $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis - $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema - $2.5 billion in 2014
ViaDerma has had Clinical success in a very short time frame. We see the use of many drugs along with our "Proprietary Transdermal Delivery System" for the treatment and continuing studies looks very promising and demonstrates efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community. We are also in early-stage discussion with two companies to private label Viabecline for distribution in the Middle East, Asia and North Africa, and Europe," said Dr. Christopher Otiko, ViaDerma's founder and CEO."

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

January 11, 2017
~Filed a patent application with the USPTO for its proprietary innovative transdermal delivery system~
http://www.marketwired.com/press-release/viaderma-incs-ceo-files-new-patent-application-signs-two-licensing-deals-locates-product-otc-pink-vdrm-2187878.htm

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129386093
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129283860

February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 21-23, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm

https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163

November 30, 2016
"Patent Pending Transdermal System" can deliver medications and nutrients into the body through the skin. The solution combined with FDA registered drugs can increase the absorption as much as 100 times directly to the localized treatment areas,
http://www.marketwired.com/press-release/viaderma-inc-clinical-studies-abroad-europe-middle-east-asia-show-promising-results-otc-pink-vdrm-2179850.htm


February 15, 2017
~ Additional patents are being filed in the MMJ space! ~
http://www.marketwired.com/press-release/viaderma-inc-looks-file-additional-patents-license-new-products-its-mmj-medical-marijuana-otc-pink-vdrm-2196107.htm

http://www.thedailychronic.net/2017/68842/clinical-trial-thcv-lowers-blood-sugar-levels-in-type-2-diabetics/
http://www.thedailychronic.net/2017/69698/study-medical-cannabis-patients-reduce-their-use-of-opioids/
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129340717
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129277006
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129022846
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129017714